Polycythemia vera and management of the thrombotic risk: an update

Published: 20 December 2023
Abstract Views: 1755
PDF: 242
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Most read articles by the same author(s)
- Massimo Franchini, Daniele Focosi, The changing landscape of treatment for acquired hemophilia A , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. 1 (2025)
Similar Articles
- Anna Maria Gori, Eleonora Camilleri, Alessia Bertelli, Angela Rogolino, Francesca Cesari, Elena Lotti, Tommaso Capobianco, Walther Iannotti, Betti Giusti , Rossella Marcucci, Pleiotropic effects of anti-thrombotic therapies: have direct oral anticoagulants any anti-inflammatory effect? , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 3 (2022)
- Sarah Gallitto, Thomas C. Varkey, Jacob Lahti, Venous thromboembolism prophylaxis in orthopedic surgery: a narrative review , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. 3 (2024)
- Luca Puccetti, Vincenzo Sammartano, Federico Caroni, Margherita Malchiodi, Paola Calzoni, Eleonora Franceschini, Lucrezia Galasso, Monica Bocchia, Safety of COVID-19 mRNA vaccination in patients with history of acquired hemophilia A: a case series , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 3 (2022)
- Ottavia Borghese, Claudio Vincenzoni, Commentary on “Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT): a multicenter, open-label, randomized controlled trial” , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. 2 (2024)
- Paola Binetti, Thrombotic thrombocytopenic purpura: much done, but still a lot to do , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. 2 (2024)
You may also start an advanced similarity search for this article.